New pill combo shows promise in slowing advanced breast cancer
NCT ID NCT05375461
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding the experimental drug TQB3616 to standard hormone therapy (fulvestrant) can help slow cancer growth in people with a common type of advanced breast cancer (HR-positive, HER2-negative). About 293 women took part, receiving either the drug combo or a placebo plus fulvestrant. The main goal was to see how long the cancer stayed under control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR-POSITIVE,HER2-NEGATIVE IN ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hosptital
Beijing, Beijing Municipality, 100142, China
-
The Fifth Medical Center of PLA General Hospital
Beijing, Beijing Municipality, 100039, China